title: Type I interferons in anticancer immunity.
abstract: Type I interferons (IFNs) are known for their key role in antiviral immune responses. In this Review, we discuss accumulating evidence indicating that type I IFNs produced by malignant cells or tumour-infiltrating dendritic cells also control the autocrine or paracrine circuits that underlie cancer immunosurveillance. Many conventional chemotherapeutics, targeted anticancer agents, immunological adjuvants and oncolytic viruses are only fully efficient in the presence of intact type I IFN signalling. Moreover, the intratumoural expression levels of type I IFNs or of IFN-stimulated genes correlate with favourable disease outcome in several cohorts of patients with cancer. Finally, new anticancer immunotherapies are being developed that are based on recombinant type I IFNs, type I IFN-encoding vectors and type I IFN-expressing cells.
authors.affiliation: 1] [2] INSERM, U1015, F-94800 Villejuif, France. [3] Université Paris Sud/Paris XI, Faculté de Médecine, F-94270 Le Kremlin Bicêtre, France. [4] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, F-94800 Villejuif, France. [5].
authors.forename: Laurence
authors.initials: L
authors.lastname: Zitvogel
authors.affiliation: 1] [2] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, F-75006 Paris, France. [3] INSERM, U1138, F-75006 Paris, France. [4] Université Paris Descartes/Paris V, Sorbonne Paris Cité, F-75006 Paris, France. [5] Université Pierre et Marie Curie/Paris VI, F-75006 Paris, France. [6].
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Galluzzi
authors.affiliation: 1] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, F-75006 Paris, France. [2] INSERM, U1138, F-75006 Paris, France. [3] Université Paris Descartes/Paris V, Sorbonne Paris Cité, F-75006 Paris, France. [4] Université Pierre et Marie Curie/Paris VI, F-75006 Paris, France. [5] Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, F-94800 Villejuif, France.
authors.forename: Oliver
authors.initials: O
authors.lastname: Kepp
authors.affiliation: 1] Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston QLD 4006, Australia. [2] School of Medicine, University of Queensland, Herston QLD 4006, Australia.
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Smyth
authors.affiliation: 1] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, F-75006 Paris, France. [2] INSERM, U1138, F-75006 Paris, France. [3] Université Paris Descartes/Paris V, Sorbonne Paris Cité, F-75006 Paris, France. [4] Université Pierre et Marie Curie/Paris VI, F-75006 Paris, France. [5] Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, F-94800 Villejuif, France. [6] Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, F-75015 Paris, France.
authors.forename: Guido
authors.initials: G
authors.lastname: Kroemer
mesh_terms: D000818:Animals; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007370:Interferon Type I / Q000276:immunology* / Q000627:therapeutic use; D009369:Neoplasms / Q000276:immunology*
chemical_list: D007370:Interferon Type I